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Abstract

Optum is a large American-based pharmacy benefit manager, healthcare consultant,
healthcare delivery service, and business analytics corporation that has dominated the industry
with sister-company UnitedHealthcare underneath the umbrella UnitedHealthGroup. This report
seeks to understand through internal and external analyses how Optum’s business model and
strategies have allowed them to gain and sustain competitive advantages in the everchanging,
volatile environment of healthcare. Specific tools used to highlight this include Porter’s Five
Forces, PESTEL, and SWOT analyses. Additionally, strategic recommendations are given for
Optum’s next steps.
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Strategic Audit
Background
Optum’s parent company, UnitedHealthGroup, is currently ranked 7on the Fortune 500
list. Its two main subsidiaries, UnitedHealthcare and Optum, individually, would be within the
Fortune 20 by their revenues, generating roughly equal amounts in 2020 (Japsen). Optum’s
network of contacts stretches to 125 million consumers, 90% of U.S. hospitals, 80% of Fortune
100 employers, 80% of U.S. health plan organizations, and all fifty U.S. state governments
(Optum). Their mission statement is about making the healthcare system work better for
everyone and to help people live healthier lives. Their core values are integrity, compassion,
relationships, innovation, and performance – highlighting the emotional connections to its work
and strict adherence to ethical business behavior.

Timeline
Optum is a fairly new company, only being officially created in April 2011 by
UnitedHealthGroup. However, Optum’s original branches and individual components were older
companies. First, in 1998, UnitedHealthGroup formed a health informational technology sector
known as Ingenix and a specialized care services branch (UnitedHealthGroup). These became
known as OptumInsight and OptumHealth, respectively. In 2005, UnitedHealthGroup bought a
health plan, with an included pharmacy benefit manager, called PacifiCare and later incorporates
it into Optum under the name OptumRx (BaileySouthwell). Together, OptumInsight,
OptumHealth (recently now being called OptumCare), and OptumRx form the three main
branches of Optum.
After the unification under the Optum name in 2011, Optum began acquiring other
companies from 2013 to 2018. These include MedExpress, Catamaran, and DaVita Medical

Group. Following all these acquisitions, in 2018, Optum became the largest employer of
physicians, having nearly 42% of them in their portfolio (BaileySouthwell).

Business Model
Optum is a multifaceted company that offers a wide range of services and products to a
wide range of consumers and organizations. First, Optum owns several medical care providers
such as private practices, surgery centers, and ambulatory/urgent care sites across the country
(Japsen). They capitalize on these business units by offering complementary value-based medical
benefits that intend to utilize these providers efficiently, for both financial and consumer
wellness reasons. For example, Optum uses financial incentives to guide those under
UnitedHealth’s insurance plans to correctly utilize their resources, such as going to a physician
for the flu instead of going to the emergency room (Japsen). Not only does this cut costs for
Optum but reduces cost-sharing (premiums) for the consumer as well.
Next, Optum offers data analytics consulting to UnitedHealth for its insurance plans to by
consulting with them on which plans and providers to improve, cut, add, or modify to connect
the optimal number of providers and consumers. Using these analytics for competitive
evaluations, Optum can incentivize providers to offer the best care they can, or risk losing on a
substantial number of potential patients (and thus revenues). Also, Optum works as a pharmacy
benefit manager, or ‘PBM’, in managing the tiering and rebates systems with major
pharmaceutical companies as well as assisting consumers in finding the right, price-effective,
quality drugs to use (Morse). This is especially important with developmental or experimental
drugs that have few substitutes and are thus vulnerable to extreme price volatility and
subjectivity. By having interests from the supply of the drug all the way to the prescription of it,

Optum has mastered vertical integration and continues to provide a wide array of services to
benefit all those involved in the complex healthcare system.
Lastly, Optum does not offer insurance products and is thus not an insurer. Because of
this label, they are free from the heavy regulations in the insurance industry that dictate how they
allocate their money – specifically towards medical costs (Morse). This gives them the flexibility
to adjust their expenditures given the environment around them – offering a serious competitive
advantage in the market.

PESTEL Analysis (Macroenvironment)
Political
The political climate for any affiliate to the healthcare industry is subject to mass,
growing criticism. Much of the current healthcare system is convoluted and difficult to navigate,
leaving room for political agendas to organize in order to rectify the system by removing the
“middlemen” or pharmacy benefit managers (PBMs). The PBM negotiates for a discount
(rebate) from drug manufacturers in exchange for a preferred tier in their plans. Since drug
manufacturers want to provide the illusion of a savings for the PBM, they artificially price their
drugs higher (Kane). However, critics of PBMs argue that this is a natural financial incentive on
the drug manufacturers’ end, and the solution would be to remove PBMs from the equation
altogether (Kane).
On the more radical end, there are political calls for the transition to a single-payer or
universal healthcare system. Proponents of this argue the current system is both inequitable and
grossly overpriced. In fact, the U.S. spends more on health care per person ($9990) than any
other country in the world, as of 2015 (Axene Health Partners). Some argue that this is due to the
difference in the quality of care provided, but others claim it’s just fueled by corporate greed and

unneeded, expensive procedures and treatments (Harrison). They also argue that healthcare
should not be a capitalist market as it’s heavy-handed in favor of providers versus consumers
given consumers’ reliance on needing healthcare no matter the cost (Harrison). Thus, the risk for
political movements to strengthen and potentially find their way through the legal system
remains high for the PBM industry.
Economic
Economically speaking, COVID-19 has caused serious damage to nearly every industry.
Daily treasury rates have been in steady decline since March, the initial outbreak of COVID-19
worldwide (U.S. Department of Treasury). Given the lockdowns and social distancing
restrictions on everyday life, the economy has slowed to a standstill. In relation to healthcare and
PBMs, this has been seen in a dramatic drop in the number of doctor’s visits and consequently
healthcare claims across all regions in the U.S. (Mehrotra). Telehealth has become a viable
substitute for many but has not mitigated for the decrease in doctor’s visits (Mehrotra). It’s
reasonable to assume that this current recession will continue as long as the pandemic remains
rampant, so the economic outlook for all industries is poor and unpredictable.
Social
Numerically based data analytics algorithms have come under criticism for their implied
sanction of biases and systemic racial disparities. While driven by numbers and not people, some
argue these algorithms have created outputs that seem to validate these biases and perpetuate
them. For instance, recently a largely used algorithm used to predict health needs for different
demographics found that black patients incurred $1800 less than their white counterparts (Paul).
This would lead to the conclusion that black people are healthier. However, this rush to a causeand-effect relationship resembles racial biases as this would be the standard level of care for

black patients. So, when they require additional care, the algorithm, and thus insurers, would flag
it as potentially unnecessary (Paul).
These algorithmic issues coupled with the recent racial tensions and riots in past months
creates a sensitive and fragile social system that companies will need to tread through carefully
and compassionately. Without proper consideration for these societal issues, healthcare
companies could have public relations and ethical issues.
Technological
Big data has touched practically every industry. The collection and analysis of big data
advise managers about the next strategic steps and potential threats. PBMs and healthcare
insurers maintain critically important claims data to regulate pricing and determine premiums for
various plans and demographics. Thus, data analytics play a central role in much of the
healthcare system at large. Recently, big data analytics has seen improvements in the
organization and accessibility of big data. Before, data would need to be collected through the
merging of several independent databases that have different ways of recording information.
Now, in the medical and insurance-related fields, data is grouped into a few, massive databases
with a newfound sense of consistency (Baillie). Some have concerns regarding data privacy with
such centralized databases but by using a “federated model”, data is accessed privately and
securely (Baillie). This has revolutionized the speed, efficiency, and accuracy of big data
analytics for the health industry.
Connected to big data, machine learning and artificial intelligence have become prevalent
as well. Typically, big data is used to monitor historical trends and then used to predict the
future. However, with machine learning, this can become not only faster but incredibly more
accurate. Using an artificial neural network (ANN), machines can essentially “learn” how to

make better and better predictions over time with a constant stream of new information (Tardif).
While this continues to be a rapidly growing practice, not many companies have explicitly
admitted to using it. Nonetheless, it remains a hot topic in the macroenvironment and a
foreseeably advantageous opportunity for those companies whose operations are heavily
intertwined with big data analytics.
Environmental
While many healthcare-related corporations have environmental campaigns and
initiatives, the environment plays little role in influencing their business decisions. However, if
the perspective is to be broadened to the international market, the effect of pollution on a
country’s population would be a worthwhile topic to further explore.
Legal
In mid-September, President Donald Trump addressed the crisis of rising Medicare drug
prices in the U.S. by signing an executive order to regulate them (Keith). The order state that
since “Americans pay more per capita for prescription drugs than residents of any other
developed country”, the government must step in (The White House). To combat the rising
prices, the executive order states that prescription drugs will be priced no more than the “mostfavored-nation price”, after adjustments for volume and GDP (The White House). The
candidates for being the most-favored-nation include both American and foreign drug
manufacturers that sell to members of the Organization for Economic Cooperation and
Development, or OECD (The White House). Drug manufacturers were staunchly against this
executive order, but according to White House spokesman Judd Deere, they failed to provide any
counterproposals, so no negotiations took place (Keith).

This has a tremendous effect on the entire chain of the healthcare industry as new, foreign
competition has been introduced into the market. This could force pricing to become more stable
and lower, or open the gateway for foreign drug manufacturers to cut corners to provide the
cheapest alternatives. Either way, this changes the legal landscape tremendously and alters the
assumptions that many healthcare insurers and PBMs currently make.

Porter’s Five Forces Analysis (Industry-Specific)
Although Optum operates in various industries and continues to enter new markets, this
analysis will be restricted to the PBM industry as this is the heart of Optum’s business model.
Industry Rivalry
The U.S. pharmacy benefit management industry has approximately 414 businesses
within it and operates with a market size of roughly $392 billion (IBISWorld). However, there
are large discrepancies between the size of the individual companies as three of them dominate
the field by providing services to insurers that cover 70% of Americans (Kane). Notably, this
industry is seeing a growing trend of merging with healthcare insurers and those that provide
medical benefits (Hirc). The main competition driver results from their network of relationships
with suppliers, healthcare insurers, healthcare providers, and consumers. These relationships are
rooted in experience and trust, thus limiting the amount of intense rivalry in this industry.
Threat of New Entrants
With this reliance on a complex relationship system, new entrants face tremendous
challenges in entering the market. First, they must establish themselves as trustworthy since
companies give them company and client data for them to analyze. Second, they must achieve
economies of scale to provide analytics and processing at a speed comparable to internal

analytics (IBISWorld). Third, they must have sufficient technology to compete with the most
widely used predictive medical algorithms to offer value to any potential consumer.
However, opportunities do exist for new entrants if they can find ways to overcome
current problems in the PBM industry. For instance, if they can find ways to incentivize patients
to utilize the proper drugs and methods of care, they could stand out (Hirc). Additionally, if they
can enhance the speed of their processes or charge a vastly lower fee, they could steal clients
away from their established relationships. Nevertheless, the threat of new entrants remains low
given the low likelihood of a new company performing better than established ones in this
industry.
Threat of Substitution
The threat of substitution is low as PBMs are considered a normal player in the
healthcare system for processing, analytics, and benefit management needs. Technology
currently complements PBMs’ analytics, but, if it were to require little human supervision, it
could become a substitution. However, many deem that scenario to not be likely until far into the
future (Baillie).
Instead, there is a threat of industry elimination. As mentioned in the political section of
the PESTEL analysis, there have been calls to remove any unnecessary “middlemen” in the
healthcare process to allow for greater drug accessibility. If this movement continues to grow in
popularity, the need for a PBM could be in danger. However, this would not imply the PBMs
would go bankrupt, but rather be incorporated into existing healthcare insurers and stripped of
certain privileges such as tiering and rebating with drug manufacturers.

Bargaining Power of Suppliers
Pharmaceutical manufacturers can either sell to PBMs or directly to the consumer.
However, since many consumers don’t usually elect to pay for a prescription completely out-ofpocket, most must be reached through insurers, and thus through PBMs (Kane). Therefore, the
bargaining power of suppliers is extremely low. Pharmaceutical manufacturers need to earn back
their heavy research and development costs while they still own the drug patent, so while they
might have to offer a less-than-ideal price, they have to reach a large consumer base to generate
any substantial revenue. However, this can be circumvented if they have a healthy relationship
with a PBM who is generous with their rebate demands and tiering. Nevertheless, their
bargaining power is weak compared to the bargaining power of the PBM in these exchanges.
Bargaining Power of Buyers
While PBMs might be able to exert power over their suppliers, their buyers (usually
healthcare insurers or benefit providers) have substantial leverage. PBMs serve to process and
pay prescription drug claims, but if this can be managed internally for cheaper, PBMs can
become obsolete. This would require the insurer to take on the responsibilities of negotiating
directly with the drug manufacturers themselves, but this would not be a far cry from the realm
of possibility – especially for those of tremendous size. Therefore, the bargaining power of
buyers is moderate as their current, already overwhelmed system is somewhat dependent on the
PBM for efficiency, but not completely dependent.

SWOT Analysis (Internal to Optum)
Strengths
One of Optum’s key strengths lies in their vertical integration tactics and implementation.
To analyze this, we must take a step up the corporate ladder to Optum’s parent:

UnitedHealthGroup. After UnitedHealthGroup officially “created” Optum in 2011, they took
further steps to position Optum to control the vertical value chain. They helped to initiate the
acquisition of companies in the surgical care (Surgical Care Affiliates), urgent care
(MedExpress), and primary care (DaVita Medical Group) market segments to give Optum
breadth to operate in local care delivery markets (Byers). Additionally, Optum’s data analytics
assets set them apart from their competitors as it has given them access to the largest databases,
which have records of upwards of 111 million lives worth of medical claims and patient survey
data (Optum). Optum utilizes these databases in connection to publicly available demographic
information to find key patterns and connections that can help lower their costs and generate
efficient outcomes.
Weaknesses
One of Optum’s weaknesses is their lack of complete autonomy. While they serve
various clients’ needs, they are wholly owned by UnitedHealthGroup, with an extremely strong
tie to UnitedHealthcare as their main client. This dissuades other large health insurers to enlist
Optum’s expertise and help as they might have concerns about the nature of Optum and
UnitedHealthcare’s working relationships. Next, as of 2019, Optum is in litigation against their
former executive, David Smith, for alleged leakage of trade secrets to his new employer,
Amazon, who is trying to start a joint health venture with Berkshire Hathaway and JP Morgan
(Coombs). Although damages might be rewarded in the case, the leakage cannot be undone and
depending on the material of information leaked, this could lead to new imitative strategies from
rivals in the future. Additionally, this calls into question how tight Optum’s executive board is,
and how well they can manage their growing company and growing management team.

Opportunities
Foremost, Optum has started to begin an international expansion – having clients in
South America and offices in the U.K., Ireland, and India. If continued, Optum could become a
household-name in various countries, assuming they can adapt their offerings to fit into
countries’ differing healthcare and political structures. Next, in light of COVID-19, Optum has
considerable obligations to help prepare America for the next pandemic, whenever that may be.
They have already begun this by coordinating with Google and Microsoft to conduct deep data
analytics and identify key early-warning signs that were missed for COVID-19 (Landi). Lastly,
but perhaps most importantly, Optum can expand their offerings and analysis to mental health
via telehealth and virtual counseling. In April 2020, Optum was rumored to potentially be
acquiring AbleTo, a virtual therapy provider that has skyrocketed since COVID-19’s social
distancing restrictions, to integrate and build upon their presence in the mental health sector
(Levy). If the acquisition goes through, Optum could continue to pursue related diversification
and find new patterns and connections between patients’ physical and mental wellbeing.
Threats
Despite being a dominant leader in the industry, Optum does need to be careful to
navigate the many other companies imitating their merged business structure with UnitedHealth.
This imitation strategy might not completely level the field for these new competitors, but it does
remove one of the chief barriers to entry. For instance, CVS and Aetna, Cigna and Express
Scripts, and Humana and Kindred have all merged within the last few years (Byers). One of the
major hurdles that Optum may or may not have been counting on was the antitrust laws
regarding combining a health care provider with a healthcare insurer (as Optum is labeled as
neither). However, as CVS and Aetna prepared to merge, a judge ruled that it was not an antitrust

violation which has opened the floodgates up to new opportunities for any company in the
healthcare sector looking to acquire a heavier market share (Livingston). This growing trend of
new, imitative business models will continue to threaten Optum and force them to continually
differentiate themselves from these competitors.

Strategic Recommendations
After conducting these three analyses, I have concluded upon a few key
recommendations for Optum’s senior management in terms of their future directions.
Brand Image
Optum’s brand image is strong within the industry, but the industry itself has a negative
connotation. Many Americans find the healthcare system broken, unfair, and greedy. One of the
key antagonists in these discussions is the “unnecessary” middlemen PBMs such as Optum.
Although they have not come under specific attack by the media, Optum should begin
preemptively emphasizing their importance in the healthcare value chain and generate defenses
for these critics. If Optum cannot garner public and political favor, they could quickly see
growing regulation and oversight on their operations. Additionally, the for-profit healthcare
system could be transformed or dismantled, so Optum needs to continue to diversify their
holdings in order to protect against that scenario.
Addressing the Pandemic
As mentioned in the Opportunities section of the SWOT analysis, Optum has serious
capabilities to analyze the failures in the handling of COVID-19 and help prepare the healthcare
sector and general public for the next pandemic. With their core competencies rooted in data
access and analysis, they could break away from their profit-hungry corporation image and

transition to being a quasi-public servant. This could not only improve their brand image but
would lead to a gain for all stakeholders in financial and community service goals alike.
Clientele Diversification
Optum has grown and diversified rapidly in the past few years from acquisitions,
mergers, and vertical integration. However, they haven’t grown as much with the acquisition of
new clients. While this would take some lobbying of UnitedHealthGroup executives, Optum
could seek out and build new relationships with both international and domestic insurers to
generate more business and increase their trustworthiness in being independent from
UnitedHealthcare. Adding new clients would also enhance the expertise of Optum employees as
they now have new databases and contacts to manage effectively.
Stability and Sustainability
Although Optum shows little sign of decline or distress, top management needs to be
careful not to fall into a lull of contentment when it comes to advancing the company and
exploring new opportunities. In the economy, in all sectors, we’ve seen companies grow to
become dominant players yet fade away only years later. The sustainability of Optum’s
operations is certainly feasible to assume but leadership needs to continue to be proactive in
stressing the efficiency of current operations and quality of future innovations. Additionally,
while acquisitions have gone smoothly so far, Optum needs to make sure to continue to integrate
new companies into their portfolio to not lose, or water down, their central business vision or
functional diversity. This does not exclusively apply to revenue-generating activities and
financials, but also to the relationships with stakeholders – particularly the patients who rely on
medical providers and knowledge that Optum helps to deploy. Managing that relationship as a

means of environmental scanning and monitoring will help Optum find emergent trends and
capitalize on them quickly.

Conclusion
Optum has revolutionized the definition of a PBM and has grown quietly to be a Fortune
20 company with tremendous growth opportunities. Their current market position is strong, and
they lead in business model innovations and data analysis as evidenced by the imitation
strategies their competitors are now undertaking. Though, they must improve their brand image
and focus their objectives on sustainability if they are to survive the eventual public spotlight that
will be shined on them.

Works Cited
Adams, K. (n.d.). Optum's presence in healthcare this past year: A timeline. Retrieved November
02, 2020, from https://www.beckershospitalreview.com/healthcare-informationtechnology/optum-s-presence-in-healthcare-this-past-year-a-timeline.html
Axene Health Partners. (2019, July 02). International Healthcare Systems: The US Versus the
World. Retrieved November 1, 2020, from https://axenehp.com/international-healthcaresystems-us-versus-world/
BaileySouthwell. (2019, June 11). Chasing the Leader: Healthcare Vertical Integration follows
Optum Model. Retrieved November 01, 2020, from
https://www.baileysouthwell.com/chasing-the-leader-healthcare-vertical-integrationfollows-optum-model/
Baillie, K., Berger, M., & Brockmeier, E. (2020, October 28). The role of data in a world
reshaped by COVID-19. Retrieved November 3, 2020, from
https://penntoday.upenn.edu/news/role-data-world-reshaped-covid-19
Byers, J. (2018, April 12). Optum a step ahead in vertical integration frenzy. Retrieved
November 2, 2020, from https://www.healthcaredive.com/news/optum-unitedhealthvertical-integration-walmart/520410/
Coombs, B. (2019, January 23). UnitedHealth sues former executive for stealing trade secrets
and taking them to Amazon joint health venture. Retrieved November 4, 2020, from
https://www.cnbc.com/2019/01/23/unitedhealth-sues-ex-executive-for-taking-tradesecrets-to-amazon-health-venture.html
Harrison, J. A. (2018, August 10). The Case for A Non-Profit Single-Payer Healthcare System.
Retrieved November 2, 2020, from https://pnhp.org/news/the-case-for-a-non-profit-singlepayer-healthcare-system/
Hirc. (n.d.). Pharmacy Benefit Managers: Market Landscape and Strategic Imperatives.
Retrieved November 9, 2020, from https://www.hirc.com/pharmacy-benefit-managersmarket-landscape-and-strategic-imperatives-1
IBISWorld. (2020, June 17). Industry Market Research, Reports, and Statistics. Retrieved
November 8, 2020, from https://www.ibisworld.com/united-states/market-researchreports/pharmacy-benefit-management-industry/
Japsen, B. (2019, December 03). Optum To Provide More Than Half Of UnitedHealth's 2020
Profits. Retrieved November 01, 2020, from
https://www.forbes.com/sites/brucejapsen/2019/12/03/optum-to-provide-more-than-halfof-unitedhealths-2020-profits/

Kane, A. (2018, October). The Problem with PBMs. Retrieved November 2, 2020, from
https://www.progressivepolicy.org/wpcontent/uploads/2018/10/PPI_TheProblemsWithPBMs_2018.pdf
Keith, T. (2020, September 14). Trump Signs New Executive Order On Prescription Drug Prices.
Retrieved November 2, 2020, from https://www.npr.org/2020/09/13/912545090/trumpsigns-new-executive-order-on-prescription-drug-prices
Landi, H. (2020, October 13). Google, Optum, Microsoft team up on $13M challenge to prevent
next pandemic. Retrieved November 3, 2020, from
https://www.fiercehealthcare.com/tech/google-optum-microsoft-and-cambridge-team-up13m-challenge-to-prevent-next-pandemic
Levy, A., & Farr, C. (2020, April 27). UnitedHealth's Optum is in advanced talks to acquire
remote mental health provider AbleTo for about $470 million. Retrieved November 6,
2020, from https://www.cnbc.com/2020/04/27/unitedhealth-near-buying-telehealthprovider-ableto-for-470-million.html
Livingston, S. (2019, September 04). Federal judge signs off on CVS-Aetna merger after postdeal review. Retrieved November 1, 2020, from
https://www.modernhealthcare.com/mergers-acquisitions/federal-judge-signs-cvs-aetnamerger-after-post-deal-review
Mehrotra, A. (2020, May 19). What Impact Has COVID-19 Had on Outpatient Visits? Retrieved
November 1, 2020, from
https://www.commonwealthfund.org/publications/2020/apr/impact-covid-19-outpatientvisits
Morse, S. (n.d.). Secret weapon: UnitedHealth's Optum business is laying waste to old notions
about how payers make money. Retrieved November 02, 2020, from
https://www.healthcarefinancenews.com/news/secret-weapon-unitedhealths-optumbusiness-laying-waste-old-notions-about-how-payers-make-money
Optum. (2013). Retrospective Database Analysis. Retrieved November 1, 2020, from
https://www.optum.com/content/dam/optum/resources/productSheets/RetrospectiveDatabase-Analysis.pdf
Optum. (n.d.). We create a healthier world. Retrieved November 01, 2020, from
https://www.optum.com/about-us.html
Paul, K. (2019, October 25). Healthcare algorithm used across America has dramatic racial
biases. Retrieved November 4, 2020, from
https://www.theguardian.com/society/2019/oct/25/healthcare-algorithm-racial-biasesoptum

Tardif, A. (2020, November 11). Investing in Artificial Intelligence (AI) – Everything You Need
to Know. Retrieved November 14, 2020, from https://www.securities.io/investing-inartificial-intelligence-ai-everything-you-need-to-know/
The White House. (2020, September 13). Executive Order on Lowering Drug Prices by Putting
America First. Retrieved November 1, 2020, from
https://www.whitehouse.gov/presidential-actions/executive-order-lowering-drug-pricesputting-america-first-2/
UnitedHealthGroup. (2020, February 24). UnitedHealth Group Announces "Optum" Master
Brand for its Health Services Businesses. Retrieved November 01, 2020, from
https://www.unitedhealthgroup.com/newsroom/2011/0411optum.html
U.S. Department of the Treasury. (2020, November 17). Daily Treasury Yield Curve Rates.
Retrieved November 9, 2020, from https://www.treasury.gov/resource-center/data-chartcenter/interest-rates/Pages/TextView.aspx?data=yield

